Immix Biopharma (NASDAQ:IMMX) Stock Price Down 4.5% - Here's WhyMarket Beat·Aug 14 at 12:00 PMIMMX+7.42%
Immix Biopharma publishes corporate presentation on NXC-201 BCMA CAR-T in relapsed/refractory AL amyloidosisPUBT·Aug 10 at 02:31 PMIMMX+7.42%
Regulatory and Data Risks Loom Over Immix Biopharma’s Clinical Programs and ValuationTip Ranks·Aug 10 at 01:00 AMIMMX+7.42%
Immix Biopharma, Inc. Q2 2026: Net loss $(11.56) M, EPS $(0.18) — 10-Q SummaryTradingView·Aug 7 at 04:11 PMIMMX+7.42%
Immix Biopharma Q2 FY26 net loss widens to USD 11.56 million; G&A expense more than doubled to USD 7.12 millionPUBT·Aug 7 at 04:06 PMIMMX+7.42%
Immix Biopharma to attend Morgan Stanley Global Healthcare Conference, host investor meetingsPUBT·Aug 4 at 08:15 AMIMMX+7.42%MS+1.21%
Immix Biopharma (NASDAQ:IMMX) Coverage Initiated at Needham & Company LLCMarket Beat·Jul 22 at 07:12 AMIMMX+7.42%
Immix Biopharma posts corporate presentation highlighting NXC-201 CAR-T in relapsed/refractory AL amyloidosisPUBT·Jul 3 at 10:50 AMIMMX+7.42%
Immix Biopharma Analyst Bullish But Flags Safety, Adoption Questionsbenzinga_article·Jun 18 at 12:38 PMIMMX+7.42%
Immix Biopharma, Inc. Stock 12‑Month Price Target Raised to $19.79, Implies 117% UpsideTradingView·Jun 18 at 08:20 AMIMMX+7.42%
This Talen Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursdaybenzinga_article·Jun 18 at 06:45 AMIMMX+7.42%TRNO-0.68%
Immix Biopharma publishes corporate presentation highlighting NXC-201 CAR-T in relapsed/refractory AL amyloidosisPUBT·Jun 17 at 12:09 PMIMMX+7.42%
Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common StockUnusual Whales·May 31 at 04:44 PMIMMX+7.42%IXJ+0.54%
